ClinicalTrials.gg
Enrolling by invitationNCT06971835Updated Oct 19, 2026

INDUCE: A Prospective 2-Year Spine Registry

An observational study in Subjects Treated With NMP as Part of Their Spine Surgery and Degenerative Disc Disease (DDD), sponsored by Red Rock Regeneration Inc.. Enrolling by invitation at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Red Rock Regeneration Inc. · Observational

How we know

Updated Oct 19, 2026Eligibility revised1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
3rd of 91
1,000 · median 118
Started
2026
with 9 others
Observational
91 of 232
19 open now
Primary completion
2028-12
later than 47 of 57 live
Registered
221st of 232
by date

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 3rd largest by planned enrollment of the 91 observational ones that give a count, is one of 10 that started in 2026, is one of 91 observational ones, reaches primary completion later than 47 of the 57 other live ones, and was the 221st registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this prospective, observational registry study is to evaluate the safety and effectiveness of Natural Matrix Protein® (NMP®) when used to promote fusion in the cervical or lumbar spine.

The secondary objective is to assess patient reported outcomes following the use of NMP in the treatment of the spine.

Read the detailed description

This is a multicenter, observational, prospective registry study of up to 1,000 patients across a maximum of 10 US sites. All subjects who meet study entrance criteria and planned to be treated with NMP Fibers and/or Micro Particulates as part of their cervical or lumbar spinal surgery will be invited to participate in the study.

PRIMARY ENDPOINTS

  • Safety - freedom from product-related serious adverse events and subsequent surgical interventions at the treated level(s)
  • Effectiveness - presence of fusion as measured by x-rays and if available CT.

SECONDARY ENDPOINTS

Beyond the primary endpoints, the following data may be collected and analyzed including, but not limited to, the following variables:

  • Baseline demographics and medical history
  • Duration of hospitalization
  • Operative time
  • Estimated blood loss
  • Neurological status
  • Subject patient reported outcomes as applicable including, but not limited to:

    • Oswestry Disability Index (ODI)/ Neck Disability Index (NDI)
    • Visual Analog Scale (VAS) Pain
    • Veteran Rand 12-Item Health Survey (VR-12)
03

Conditions studied

  • Subjects Treated With NMP as Part of Their Spine Surgery
  • Degenerative Disc Disease (DDD)

Keywords

  • degenerative spine
  • NMP
  • Induce
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study will include a maximum of 10 US sites, covering a large geographic region, representing a diverse demographic cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Implanted on-label with NMP in at least one vertebral level in the cervical (C1-C7) or lumbar (L1-S1) spine as part of their surgery
  2. Total volume of bone graft or bone graft substitute used in index surgery must contain at least 50% NMP by volume per treated level, where NMP is mixed with other graft material.
  3. Skeletally mature (age≥18 years of age)
  4. Be willing to sign the study-specific document prior to index surgery

Exclusion criteria

Exclusion Criteria:

  1. Not willing to sign the study-specific document prior to index surgery
  2. Use of allogenic growth factor extacts (i.e. OsteoFactor/ProteiOS), Demineralized Bone Matrix (DBM), or cell based allografts as part of the index surgery (use of autograft or bone marrow aspirate (BMA) is allowed)
  3. Use of rhBMP-2 (i.e. INFUSE) or synthetic peptide enhanced graft (i.e. iFactor) as part of the index surgery
  4. Diagnosis of spinal deformity (greater than 20 degrees) or vertebral fracture including treated level
  5. Unable to comply with postoperative standard of care imaging (e.g. pregnant or nursing female)
  6. Did not complete baseline patient reported outcomes prior to index surgery
  7. Incarcerated at the time of surgery or preoperative evaluation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects treated on-label with NMP as part of their spine surgery.

    Subjects implanted on-label with NMP in at least one vertebral level in the cervical (C1-C7) or lumbar (L1-S1) spine as part of their surgery.

    Device: NMP

Interventions

  • DeviceNMP

    The study product is Induce Biologics NMP Fibers and NMP Micro Particulates however, this is observational research that involves standard of care. NMP is regulated as a human cellular or tissue-based product (HCT/P) under section 361 of the Public Health Service (PHS) Act and in 21 CFR Part 1271. Under this regulation it did not require clinical evaluation before it could be used commercially. It is indicated for use "as a bone void filler for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the boney structure.

06

What researchers measure

Primary outcomes

  1. Fusion

    Incidence of fusion at treated levels as measured by x-rays and if available CT, will be reported.

    Time frame: 6 month and 12 month post surgery, and 24 month post surgery

  2. Serious Adverse Events and Subsequent Surgical Interventions

    Incidence of serious adverse events (SAE) and subsequent surgical intervention (SSI) will be reported.

    Time frame: Through study completion, an average of 2 years.

Secondary outcomes

  1. Change in Pain

    Pain scores will be reported as assessed by Visual Analog Scale scores, (0-100mm) or Numeric Rating Scale (0-10) depending on institutions standard of care. Higher score indicates increased pain.

    Time frame: Baseline, 3 month, 6 months, 12 months, and 24 months postop

  2. Change in Disability

    Disability improvement as measured by Oswestry Disability Index (ODI) or Neck Disability Index (NDI), as applicable, 0-100%. High score indicates increase disability.

    Time frame: Baseline, 3 month, 6 months, 12 months, and 24 months postop

  3. Change in Quality of Life

    Improvement in qualify of life as measured by Veterans Rand-12, 0-100. High score indicates increase quality of life.

    Time frame: Baseline, 3 month, 6 months, 12 months, and 24 months postop

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 80 observational studies under Intervertebral Disc Degeneration, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 84. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 14, 2025
StartActual
Feb 17, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Huntsman Spinal Clinic · Salt Lake City, United States
Oct 19, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedUse of allogenic growth factor extacts (i.e. OsteoFactor/ProteiOS), Demineralized Bone Matrix (DBM), or cell based allografts as part of the index surgery (use of autograft or bone marrow aspirate (BMA) is allowed)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added
    Show site
    • Huntsman Spinal Clinic · Salt Lake City, United States
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedUse of allogenic growth factor extacts (i.e. OsteoFactor/ProteiOS), Demineralized Bone Matrix (DBM), or cell based allografts as part of the index surgery (use of autograft or bone marrow aspirate (BMA) is allowed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06971835
Lead sponsor
Red Rock Regeneration Inc.
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Feb 17, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion